Remove how-to-patent-in-europe-epo
article thumbnail

How the UPC and European Patents with Unitary Effect Reach Beyond Europe to the United States

IP Watchdog

The impact of the long-awaited launch of the Unified Patent Court (UPC) is hard to overstate. While litigators and patent portfolio managers are immediately feeling the impact in Europe, surprisingly, they should also expect an impact on information disclosure statement (IDS) strategy for U.S. patent applications.

article thumbnail

Should you need at least a 4-year scientific degree to be a patent attorney?

The IPKat

Earlier this year, the Institute of Professional Representatives before the European Patent Office (epi) proposed a radical raising of the admission requirements for the European patent attorney qualifying examinations (EQEs). Unsurprisingly, the epi proposal has been met with dismay and consternation by the patent profession.

Patent 106
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

US Supreme Court decision in Amgen v Sanofi: The European Perspective

The IPKat

The US Supreme Court recently ruled in the high profile Amgen versus Sanofi patent dispute. 2021 ), the Supreme Court found Amgen's function and epitope defined PCSK9 antibody patents to lack enablement ( Amgen Inc v Sanofi, No. The patents in dispute in Amgen v Sanofi defined a class of antibodies by their function and epitope.

article thumbnail

Building High-Quality Patent Portfolios in the United States and Europe: Part II – Software Patents

IP Watchdog

In Part I of this series, we discussed how patent portfolio managers should be careful when generating company-owned prior art or reviewing competitor prior art, and how a patent litigation or licensing campaign can be significantly hamstrung based on how the United States and Europe consider intervening prior art.

Patent 96
article thumbnail

Broad functional claiming at the EPO (T 0835/21)

The IPKat

The ever-present question for IP in certain technical fields is how much data is needed to support a patent application. However, in some cases, the amount of data needed to overcome this doubt to support a patent application may still be surprisingly minimal. Neither the structures or sequences of these examples was provided.

Invention 112
article thumbnail

Never Too Late: If you missed the IPKat last week!

The IPKat

Katfriend Hans Eriksson shared insights into how the intellectual property strategy of high-end watchmakers had responded to the trend of customization or personalization of luxury timepieces. He provides some timely reflections on the recent trade mark infringement cases in the US and Europe. Image from Pixabay.

article thumbnail

Patenting Antibodies: The epitope claim is dead, long live the epitope claim

The IPKat

Antibodies may be defined in a patent claim by their amino acid sequence or by the sequence of the target (epitope) to which the antibody binds. Historically, epitope claims were relatively common in the field of antibody patents, as they represented a way of broadly protecting any antibody that bound the same epitope.

Patent 94